PDF herunterladen
Nervenheilkunde 2004; 23(09): 514-520
DOI: 10.1055/s-0038-1626416
Original- und Übersichtsarbeiten - Original and Review Articles
Schattauer GmbH

Pharmakologische Möglichkeiten der Rückfallprophylaxe bei Nikotinabhängigkeit[*]

Pharmacological strategies of the relapse prophylaxis of nicotine dependence
D. Nowak
1   Institut und Poliklinik für Arbeitsund Umweltmedizin der Universität München (Direktor: Prof. Dr. med. D. Nowak)
,
V. Bäuerle
1   Institut und Poliklinik für Arbeitsund Umweltmedizin der Universität München (Direktor: Prof. Dr. med. D. Nowak)
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
18. Januar 2018 (online)

    Lizenzen und Reprints

Zusammenfassung

Die Nikotinersatztherapie (Pflaster, Kaugummi oder Spray) hat einen wichtigen Stellenwert in der Behandlung der Nikotinsucht. Die damit erzielten Abstinenzquoten nach sechs bis zwölf Monaten schwanken je nach Darreichungsform zwischen 5 und 25%. Die Wirksamkeit dieser Verfahren beruht auf einer Reduktion von Entzugserscheinungen durch Stimulation der nikotinischen ACh-Rezeptoren. Als erste nicht-nikotinhaltige Substanz erhielt Bupropion SR (»slow release«) die Zulassung zur Raucherentwöhnung. In einer kontrollierten Studie waren ein Jahr nach Therapieende mit diesem selektiven Dopamin- und Noradrenalin-Wiederaufnahmehemmer noch 30% der Patienten abstinent. Somit stehen nun mehrere viel versprechende Ansätze zur Rückfallprophylaxe bei Nikotinabhängigkeit zur Verfügung.

Summary

Nicotine replacement therapy (patches, gum, or spray) is effective part of a pharmacological strategy to treat nicotine dependence. Meta-analyses have demonstrated 6-12 month absistence rates between 5 and 25%, depending on the mode of application and on the given dose. With increasing knowledge of mechanisms how nicotine interacts with the central nervous system, a variety of non-nicotine drugs has been tested for smoking cessation. Bupropion SR (slow release) was the first medicine as non-nicotine drug for treatment of nicotine dependence. Bupropion which selectively blocks noradrenaline and dopamine re-uptake has proven to be successful with abstinence rates of 30% after 12 months treatment. Thus, several compelling therapeutic strategies exist in pharmacological treatment of nicotine dependence.

Schlüsselwörter

Nikotin - Nikotinabhängigkeit - Nikotinersatztherapie - nikotinhaltige Medikamente - nikotinfreie Medikamente - Raucherentwöhnung

Keywords

Nicotine - nicotine dependence - nicotine replacement therapy - nicotine drugs - non-nicotine drugs - smoking cessation

* aktualisierte Fassung der Arbeit: Schön S, Nowak D. Medikamentöse Verfahren zur Raucherentwöhnung. Suchtmed 2002; 4: 189-99.


 

  • Literatur

  • 1 Arzneimittelkommission der Deutschen Ärzteschaft. Empfehlungen zur Therapie der Tabakabhängigkeit. Arzneimittelkommission der Deutschen Ärzteschaft. 2001; 1-26.
    PubMedGoogle Scholar
  • 2 Balfour DJK, Fagerström KO. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 1996; 72: 51-81.
    CrossrefPubMedGoogle Scholar
  • 3 Batra A und Buchkremer G. Nikotin. In: Gastpar M, Mann K, Rommelspacher H. Lehrbuch der Suchterkrankungen. Stuttgart: Thieme; 1999: 208-16.
    Google Scholar
  • 4 Behm FM, Schur C, Levin ED, Tashkin DP, Rose JE. Clinical evaluation of a citric acid inhaler for smoking cessation. Drug Alcohol Depend 1993; 31: 131-8.
    CrossrefPubMedGoogle Scholar
  • 5 Benowitz NL, Peng M. Non-nicotine pharmacotherapy for smoking cessation. CNS Drugs 2000; 13: 265-85.
    CrossrefGoogle Scholar
  • 6 Berlin I, Said S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V, Lecrubier Y, Puech AJ. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995; 58: 444-52.
    CrossrefPubMedGoogle Scholar
  • 7 Bourne S. Treatment of cigarette smoking with short-term high-dosage corticotrophin therapy: preliminary communication. J Roy Soc Med 1985; 78: 649-50.
    CrossrefPubMedGoogle Scholar
  • 8 Buchkremer G, Bents H, Minneker E. et al. Langfristige Effekte einer Kombination von transdermaler Nikotinzufuhr mit Verhaltenstherapie zur Raucherentwöhnung. Der Nervenarzt 1988; 59: 488-90.
    PubMedGoogle Scholar
  • 9 Dalack GW, Glassman AH, Rivelli S, Covey L, Stetner F. Mood, major depression and fluoxetine response in cigarette smokers. Am J Psychiartry 1995; 152: 398-403.
    Google Scholar
  • 10 Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology 2001; 155: 52-7.
    CrossrefPubMedGoogle Scholar
  • 11 Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA. A prospective safety surveillance study for bupropion sustainedrelease in the treatment of depression. J Clin Psych 1998; 59: 366-73.
    CrossrefPubMedGoogle Scholar
  • 12 Edwards NB, Murphy JK, Downs AD, Ackermann BJ, Rosenthal TL. Doxepin as an adjunct to smoking cessation: a double-blind pilot study. Am J Psych 1989; 146: 373-6.
    CrossrefPubMedGoogle Scholar
  • 13 Fiore MC, Kenford SL, Jorenby DE, Wetter DW, Smith SS, Baker TB. Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. Chest 1994; 105: 524-33.
    CrossrefPubMedGoogle Scholar
  • 14 Fiore MC, Smith SS, Jorenby DE. et al. The effectiveness of the nicotine patch for smoking cessation. JAMA 1994; 271: 1940-7.
    CrossrefPubMedGoogle Scholar
  • 15 Gourlay SG, Benowitz NL. Is clonidine an effective smoking cessation therapy?. Drugs 1995; 50: 197-207.
    CrossrefPubMedGoogle Scholar
  • 16 Hall SM, Reus VI, Munoz RF, Sees KL, Humfleet G, Hartz DT, Frederick S, Triffleman E. Nortriptyline and cognitive behavioural therapy for treatment of cigarette smoking. Arch Gen Psychiatry 1998; 55: 683-90.
    CrossrefPubMedGoogle Scholar
  • 17 Hays JT, Hurt RD, Rigotti NA, Niaura R. et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. Ann Intern Med 2001; 135: 423-33.
    CrossrefPubMedGoogle Scholar
  • 18 Heading CE. NicVAX (Nabi Biopharmaceuticals). IDrugs 2003; 06 (12) 1178-81.
    Google Scholar
  • 19 Hjalmarson A, Franzon M, Westin A, Wiklund O. Effect of nicotine nasal spray on smoking cessation. Arch Intern Med 1994; 154: 2567-72.
    CrossrefPubMedGoogle Scholar
  • 20 Hjalmarson A. Effect of nicotine chewing gum in smoking cessation. JAMA 1984; 252: 2835-8.
    CrossrefPubMedGoogle Scholar
  • 21 Hurt RD, Sachs DPL, Glover ED. et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195-202.
    CrossrefPubMedGoogle Scholar
  • 22 Jorenby DE, Leischow SJ, Nides MA. et al. A controlled trial of sustained-release bupropion, a nicotine patch or both for smoking cessation. New Engl J Med 1999; 340: 685-91.
    CrossrefPubMedGoogle Scholar
  • 23 Levin ED, Behm F, Carnahan E, LeClair R, Shipley R, Rose JE. Clinical trials using ascorbic acid to aid smoking cessation. Drug Alcohol Depend 1993; 33: 211-23.
    CrossrefPubMedGoogle Scholar
  • 24 Malcolm R, Currey HS, Mitchell MA, Keil JE. Silver acetate gum as a deterrent to smoking. Chest 1986; 90: 107-11.
    CrossrefPubMedGoogle Scholar
  • 25 Morrow R, Nepps P, McIntosh M. Silver acetate mouth spray as an aid in smoking cessation: results of a double-blind trial. J Am Board Fam Pract 1993; 06: 353-7.
    Google Scholar
  • 26 Nemeth-Coslett R, Griffiths RR. Naloxone does not affect cigarette smoking. Psychopharmacology 1986; 89: 261-4.
    PubMedGoogle Scholar
  • 27 Niaura R, Goldstein MG, Depue J, Keuthen N, Kristell J, Abrams D. Fluoxetine, symptoms of depression and smoking cessation [abstract]: Proceedings of the 16th Annual Scientific Sessions. Society of Behavioural Medicine. Annals Behav Medicine 1995; 17: 61.
    Google Scholar
  • 28 Palmer KJ, Buckey MM, Faulds D. Transdermal nicotine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an aid to smoking cessation. Drugs 1992; 44: 498-529.
    CrossrefPubMedGoogle Scholar
  • 29 Pomerleau CS, Pomerleau OF, Majchrzak MJ. Mecamylamine pretreatment increases subsequent nicotine self-administration as indicated by changes in plasma nicotine level. Psychopharmacology 1987; 91: 391-3.
    CrossrefPubMedGoogle Scholar
  • 30 Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998; 158: 2035-9.
    CrossrefPubMedGoogle Scholar
  • 31 Rose JE, Behm FM. Inhalation of vapor from black pepper extract reduces smoking withdrawal symptoms. Drug Alcohol Dependence 1994; 34: 225-9.
    CrossrefPubMedGoogle Scholar
  • 32 Rose JE, Behm FM, Westman EC. Brandswitching and gender effects in mecamylamine/nicotine smoking cessation treatment. Nicotine Tobacco Res 1999; 01: 286-7.
    Google Scholar
  • 33 Satoskar SD, Keyler DE, LeSage MG, Raphael DE, Ross CA, Pentel PR. Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int Immunopharmacol 2003; 03 (07) 957-70.
    CrossrefPubMedGoogle Scholar
  • 34 Schmidt LG. Tabakabhängigkeit und ihre Behandlung. Dt Ärztebl 2001; 98 (Heft 27): A 1826-33.
    Google Scholar
  • 35 Schneider NG, Olmstead R, Vaghaiwalla FMody, Doan K, Franzon M, Jarvik ME, Steinberg C. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 1995; 90: 1671-82.
    CrossrefPubMedGoogle Scholar
  • 36 Sellers EM, Naranjo CA, Kadlec K. Do serotonin uptake inhibitors decrease smoking? Observations in a group of heavy drinkers. J Clin Psychopharmacol 1987; 07: 417-20.
    Google Scholar
  • 37 Silagy C, Mant D, Fowler G, Lodge M. Metaanalysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139-42.
    CrossrefPubMedGoogle Scholar
  • 38 Silagy C, Mant D, Fowler G, Lancester T. Nicotine replacement therapy for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 2001
    Google Scholar
  • 39 Sutherland G, Stapleton JA, Russell MAH, Jarvis MJ, Hajek P, Belcher M, Feyerabend C. Randomised controlled trail of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324-9.
    CrossrefPubMedGoogle Scholar
  • 40 Tang JL, Law M, Wald N. How effective is nicotine replacement therapy in helping people to stop smoking?. BMJ 1994; 308: 21-6.
    CrossrefPubMedGoogle Scholar
  • 41 Tashkin DP, Kanner R, Bailey W, Buist S, Anderson P, Nides MA, Gonzales D, Dozier G, Patel MK, Jamerson BD. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. The Lancet 2001; 357: 1571-5.
    CrossrefPubMedGoogle Scholar
  • 42 Tennant FS, Tarver AL, Rawson RA. Clinical evaluation of mecamylaminefor withdrawal from nicotine dependence. NIDA Res Monogr 1983; 49: 239-46.
    Google Scholar
  • 43 Tønnesen P, Fryd V, Hansen M, Helsted J, Bunnersen AB, Forchammer H, Stockner M. Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking. N Engl J Med 1988; 318: 15-8.
    CrossrefPubMedGoogle Scholar
  • 44 Tønnesen P, Nørregard J, Mikkelsen K, Jørgensen S, Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 1993; 269: 1268-71.
    CrossrefPubMedGoogle Scholar
  • 45 Nicotine Study Group. Transdermal nicotine for smoking cessation. JAMA 1991; 22: 3133-8.
    Google Scholar
  • 46 Public Health Service Report. A clinical practice guideline for treating tobacco use and dependence. JAMA 2000; 283: 3244-54.
    CrossrefPubMedGoogle Scholar
  • 47 US Public Health Service Report. Clinical practice guideline. Treating tobacco use and dependence. Washington: US Department of Health and Human Services, Public Health Service; 2000 www.surgeongeneral.gov/tobacco.
    PubMedGoogle Scholar
  • 48 West R, Willis N. Double-blind placebo controlled trial of dextrose tablets and nicotine patch in smoking cessation. Psychopharmacology 1998; 136: 201-4.
    CrossrefPubMedGoogle Scholar
  • 49 Westman EC, Behm FM, Rose JE. Airway sensory replacement combined with nicotine replacement for smoking cessation: a randomized, placebo controlled trial using a citric acid inhaler. Chest 1995; 107: 1358-64.
    CrossrefPubMedGoogle Scholar
  • 50 Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD. A randomized trial of naltrexone for smoking cessation. Addiction 1999; 94: 1227-37.
    CrossrefPubMedGoogle Scholar